Figure 1.

Graphical Abstract providing an overview of the methods, results, and implication of the study. The QCC+ product demonstrated superior performance in achieving hemostasis in mild to moderate cardiac surgery bleeding compared to control. The difference between groups in the proportion of subjects achieving hemostasis was greater than 20% at both 5- and 10-minute assessment times, with no significant difference in safety outcomes. QCC+, QuikClot Control+; CABG, coronary artery bypass grafting.